MYCN and neoplasm: The absence of any significant R2* response to cabozantinib in tumours arising in the Th-MYCN/ALKF1174L mice is likely a consequence of their having a relatively poorer haemodynamic vasculature compared to the Th-MYCN mice, which we previously revealed using susceptibility MRI [16].